Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
2. Cita con resumen
Anónimo. Ruxolitinib et polycythémie essentielle. Prescrire 2016;36:246-50. [Ref.ID 100529]
4. Cita con resumen
Anónimo. FDA approves expanded use of bone marrow disorder medicine. DIA Daily 2014:5 de diciembre. [Ref.ID 98383]
5. Cita con resumen
Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197-8. [Ref.ID 95824]
6. Cita con resumen
Shah R, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503. [Ref.ID 95770]
7.
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413-26. [Ref.ID 95664]
8.
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36:295-316. [Ref.ID 95517]
10. Cita con resumen
Anónimo. Ruxolitinib (Jakafi) for myelofibrosis. Med Lett Drugs Ther 2012;54:27-8. [Ref.ID 92666]
11.Tiene citas relacionadas Cita con resumen
Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012;366:844-6. [Ref.ID 92472]
12.Tiene citas relacionadas
Vestovsek S, Mesa RA, Gotib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viltanen S, Koumenis IL, Sun W, Sandor V, Kantarijan HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807. [Ref.ID 92469]
13.Tiene citas relacionadas Cita con resumen
Harrison C, Kiladjian J-J, Kathrin H, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibitor with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98. [Ref.ID 92468]
Seleccionar todas
 
 1 a 13 de 13